This Friday, the European Commission authorized the sale of a new, third version of the Spikevax vaccine against Covid-19 from the pharmaceutical company Moderna.
Spikevax XBB.1.5 responds to new Covid-19 variants and could be used in the next autumn/winter Covid-19 vaccination campaign, which is about to begin in Member States.
Marketing authorization was granted on an accelerated basis after the European Medicines Agency gave a positive assessment.
In Portugal, vaccinations will begin on September 29 and will take place simultaneously in public pharmacies for people aged 60 and over, as well as in National Health Service (SNS) health facilities for people under 60 and at risk of illness. .
On 7 September, the European Center for Disease Prevention and Control (ECDC) warned of a recent increase in transmission of the Covid-19 virus in the European Union and the European Economic Area (EU/EEA).
“In recent weeks, evidence of SARS-CoV-2 transmission has increased from previously very low levels in the EU/EEA,” the European agency said in a statement.
Covid-19 is a pandemic respiratory disease caused by the coronavirus SARS-CoV-2, a type of virus discovered in late 2019 in China that has several variants and subvariants, some more contagious than others.
IG // ZhMR
Lusa/end
Author: Lusa
Source: CM Jornal
I am Michael Melvin, an experienced news writer with a passion for uncovering stories and bringing them to the public. I have been working in the news industry for over five years now, and my work has been published on multiple websites. As an author at 24 News Reporters, I cover world section of current events stories that are both informative and captivating to read.